Evaluate the Safety and Pharmacokinetics of Ricolinostat

Clinical trial NCT05193851 · COMPLETED

Trial details

NCT number: NCT05193851
Sponsor: Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Peripheral Nervous System Diseases

Start date: 2022-01-12
Primary completion: 2022-01-30
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.